Khan TM, Teke ME, Karakousis GC, Miura JT, et al. Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab. Ann Surg Oncol 2022 Jan 21. pii: 10.1245/s10434-021-11199.
PMID: 35061122